Understanding feeding consumption and nutrient ingestion in vegetarian diet is essential to foster nutritional adequacy. The goal was assessing Omega-3 consumption in such diets. It is a transversal study, performed with 09 vegetarian adults. The ingestion was achieved by means of 24-Hour Reminder and the nutrients were defined by nutritional software. The results disclosed that the diet is rich in ALA (alpha-linolenic acid), however the functions are performed by EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). ALA is capable of converting inefficiently in the other ones. In the present study, ALA consumption is above DRI’s (2.55g± 2.14), but when it is converted to EPA (326mg) and DHA (65.5mg) is below EFSA guidance and North American cardiovascular disease prevention and treatment guidelines. It was possible to conclude that this nutrient is essential to health, and in vegetarian diet, it is not achieved, a special care is required in diet planning.

BACKGROUND: It is widely accepted that hypertension is a pro-inflammatory disease and that the immune system plays a vital role in mediating hypertensive outcomes, end organ damages . and modulation of hypertensive pathology [2]. Patient with MetS usually present increased levels of C-reaktive protein (CRP) wich is a prototypic marker of inflammation [5], however the data of the influence of incresed levels of CRP on the control of the aterial hypertension in patients with MetS, are scarce. OBJECTIVE: We sought to determine the incresed CRP levels influence on the control of the aterial hypertension in patients with MetS. METHODS: We conducted a multicenter observational cross-sectional study. The study population recruited from a coule of outpatient clinic between june 2018 and june 2019. The population study consisted of 420 patients with MetS aged = 18 years, divided in two groups:211 with level of CRP>3mg/l , and 209 participans with CRP level <3mg/l. RESULTS: Among those with CRP level > 3mg/l(N=211) controlled BP according to evidence and current guidelines, was achieved in 23.6% of participans, whereas among those with CRP level <3mg/l(N=209) controlled BP was achived in 48.3%; p=0.000). There was independent association of CRP levels >3mg/l with uncontrolled BP (OR=3.1, 95%CI 2.06 - 4.75). There were signifiacant association of uncontrolled BP with: uncontrolled glycemia (OR =1.4,95%CI 0.97-1.84); increased BMI (OR=4.4; 95%CI 3.02-4.05) and five risk factors for MetS. (OR=2.3, 95%CI 1.93-2.81). CONCLUSIONS: We think,we brought some good evidence,in our present study ,that patients with MetS and higher CRP level have a higher prevalence of unconrolled BP.

Background: Ranolazine (RAN) reduces cardiac sodium channel 1.5’s late sodium current in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular (LV) function. RAN blocks neuro- nal sodium channel 1.7, potentially altering parasympathetic and sympathetic (P&S) activity. The effects of RAN on LV ejection fraction (LVEF) and P&S function in CHF were studied. Methods: Matched CHF patients were given open-label RAN (1000 mg po-bid) added to guideline-driven therapy (RANCHF, 41 systolic, 13 diastolic) or no adjuvant therapy (control, NORANCHF, 43 systolic, 12 diastolic). Echocar- diographic LVEF and P&S measures were obtained at baseline and follow-up (mean 23.7 months). Results: LVEF increased in 70% of RANCHF patients, an average of 11.3 units. Mean LVEF remained unchanged in NORANCHF patients. P&S measures indicated cardiovascular autonomic neuropathy (P=0.1 bpm2) in 20% of NORANCHF patients at baseline and in 29% at follow-up (increasing in both groups). At baseline, 28% of patients had high sympathovagal balance (SB), RAN normalized SB over 50% of these; in contrast, the NORANCHF group had a 20% increase in patients with high SB. Conclusions: RAN preserves or improves LVEF and decreases high SB in CHF.

Following the introduction of intracardiac repair of tetralogy of Fallot, early mortality in 1950s was as high as 25%. However, by the mid-1980s, this has reduced to 2% and currently ~ 0% even in neonates and young infants despite the risk of reoperations, a large number of studies have documented satisfactory long-term survival rates in repaired tetralogy of Fallot, with a 30-year survival rate ranging from 86% to 91.7%.

Background: The clinical impact of intracoronary thrombus aspiration (TA) during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) is unclear. We investigated to evaluate whether TA during primary PCI reduces one-year mortality. Methods: From the Korea Acute Myocardial Infarction Registry-National Institute of Health, 3749 patients with STEMI who were undergoing primary PCI within 12 hours (60.8±12.9 years, 18.7% women) and shown pre-procedural Thrombolysis In Myocardial Infarction (TIMI) flow 0, 1 in coronary angiography were enrolled between November 2011 and November 2015 during one-year follow up. The patients were divided into two groups according to TA during primary PCI: PCI with TA (n=1630) and PCI alone (n=2119). The primary end-point was major adverse cardiac events (MACE), defined as the composite of cardiovascular death (CVD), stroke or recurrent MI at one-year. The secondary efficacy end-point were all-cause of mortality and CVD at one-year. Results: PCI with TA did not reduce the risk of MACE (OR: 0.598, 95% CI: 0.737-1.160, p=0.499), all-cause mortality (OR: 0.898, 95% CI: 0.705-1.144, p=0.383) and CVD (OR: 0.893, 95% CI: 0.683-1.168, p=0.408) in all patients during one-year follow up. The trend did not change after propensity score matching. In subgroup analysis, there was no efficacy of clinical outcome during one-year follow up. Conclusions: Primary PCI with TA did not reduce MACE and all-cause mortality among patients with STEMI and pre-procedural TIMI flow 0,1 during one-year follow up.